European CHMP recommends license extension of tofacitinib (Xeljanz) for treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis

License extension is for treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs, in combination with methotrexate or as monotherapy.

European Medicines Agency